Literature DB >> 12586974

Thrombocytopenia after immunization of Canadian children, 1992 to 2001.

Taj Jadavji1, David Scheifele, Scott Halperin.   

Abstract

BACKGROUND: Thrombocytopenia occasionally follows immunization of children, especially after administration of measles-containing vaccines. The purpose of this study was to describe the clinical features of postimmunization thrombocytopenia, with emphasis on the rate of complications and outcome.
METHODS: A prospective survey was conducted by 12 pediatric centers in Canada during 1992 to 2001. At each center a nurse monitor searched for inpatient cases. Cases were defined as having onset of clinical signs or laboratory measures of thrombocytopenia (platelet count, <50 x 10(9)/l) within 30 days after immunization. Cases were described in a standardized manner, including follow-up data as available.
RESULTS: Sixty-one cases were detected, an average of 6 per year or approximately 1 case per 15,000 general hospital admissions. Median age of cases was 13 months. The mean platelet count at diagnosis was 8.6 x 10(9)/l. Most cases (79%) followed measles-containing vaccines. Only 1 child had a serious (fatal) complication. Platelet counts returned to normal within 30 days of onset in 46 of 57 children (80.7%) with information available. Five children (8.2%) had persistent or intermittent thrombocytopenia for 3 months or more.
CONCLUSION: Thrombocytopenia associated with routine immunization of children is rare and usually benign, resolving within 1 month in most children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586974     DOI: 10.1097/01.inf.0000048961.08486.d1

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  15 in total

1.  Do childhood vaccines cause thrombocytopenia?

Authors:  Laura J Sauvé; David Scheifele
Journal:  Paediatr Child Health       Date:  2009-01       Impact factor: 2.253

2.  IMPACT after 17 years: Lessons learned about successful networking.

Authors: 
Journal:  Paediatr Child Health       Date:  2009-01       Impact factor: 2.253

Review 3.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

4.  IMPACT after 17 years: Lessons learned about successful networking.

Authors: 
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

5.  Epistaxis and gross haematuria with severe thrombocytopaenia associated with influenza vaccination.

Authors:  Abdullah Almohammadi; Michael S Lundin; Calvin Abro; Borys Hrinczenko
Journal:  BMJ Case Rep       Date:  2019-05-06

Review 6.  Vaccine administration and the development of immune thrombocytopenic purpura in children.

Authors:  Valerio Cecinati; Nicola Principi; Letizia Brescia; Paola Giordano; Susanna Esposito
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

7.  The Canadian Immunization Monitoring Program, ACTive (IMPACT): Active surveillance for vaccine adverse events and vaccine-preventable diseases.

Authors:  J A Bettinger; S A Halperin; W Vaudry; B J Law; D W Scheifele
Journal:  Can Commun Dis Rep       Date:  2014-12-04

8.  Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study.

Authors:  Edeltraut Garbe; Frank Andersohn; Elisabeth Bronder; Abdulgabar Salama; Andreas Klimpel; Michael Thomae; Hubert Schrezenmeier; Martin Hildebrandt; Ernst Späth-Schwalbe; Andreas Grüneisen; Oliver Meyer; Hanife Kurtal
Journal:  Eur J Clin Pharmacol       Date:  2011-12-21       Impact factor: 2.953

Review 9.  Update on side effects from common vaccines.

Authors:  Benjamin J Song; Rohit K Katial
Journal:  Curr Allergy Asthma Rep       Date:  2004-11       Impact factor: 4.919

Review 10.  Pathobiology of secondary immune thrombocytopenia.

Authors:  Douglas B Cines; Howard Liebman; Roberto Stasi
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.